Incyte Corp (NAS:INCY)
$ 57.05 -0.55 (-0.95%) Market Cap: 12.83 Bil Enterprise Value: 9.01 Bil PE Ratio: 17.29 PB Ratio: 2.37 GF Score: 88/100

Incyte Corp at Goldman Sachs Healthcare CEOs Unscripted Conference: A View from the Top (Virtual) Transcript

Jan 06, 2022 / 08:00PM GMT
Release Date Price: $72.63 (+3.09%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon, everyone, and thank you for joining us for the Goldman Sachs CEO Unscripted Conference. We're really pleased to have Herve Hoppenot, Chairman, President and CEO of Incyte. Thank you, Herve, for joining us. Happy New Year.

Herve Hoppenot
Incyte Corporation - Chairman, President & CEO

Thank you for inviting me.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Thank you. And as we start or stand today -- as you stand today, sorry, with Jakafi, Pemazyre and Monjuvi and recently approved Opzelura and the current pipeline, what is your outlook on the overall business and where you must focus in 2022?

Herve Hoppenot
Incyte Corporation - Chairman, President & CEO

Salveen, thanks for the invitation. So 2022 is very simple. In fact, in many ways, it's about growth of revenue, and we have obviously Jakafi that is growing in its

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot